BCMA CAR-T enteritis: understanding immune toxicities in multiple myeloma
Official title: Mechanisms of BCMA CAR-T-mediated enteritis in multiple myeloma patients
Funded at University of California, San Francisco · NIH-11433305 · Data updated 2026-11-12
A broad study to uncover why some CAR-T cell treatments targeting BCMA cause severe intestinal inflammation in people with multiple myeloma.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Francisco NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project start | August 12, 2026 |
| Project end | July 31, 2031 |
| Funding year | 2026 |
| Award (this year) | $683,270 |
| NIH project number | 1R01CA316736-01 |
| Project ID | NIH-11433305 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults with relapsed/refractory multiple myeloma treated with BCMA-directed CAR-T therapy who develop or are at risk for enteritis.
✕Less likely to help
Patients without BCMA CAR-T treatment or without enteritis may not directly benefit from this research.
What this research studies
This project will look at how BCMA CAR-T cells interact with immune cells and gut tissue to cause enteritis in patients with multiple myeloma. Researchers will use advanced single-cell and spatial multi-omics on tissue and blood samples to map immune cell types and pathways involved. The goal is to identify precise targets for treatment that reduce inflammation without weakening the anti-cancer effect of CAR-T therapy.
Why it matters
Potential benefit: If successful, the findings could lead to targeted therapies that prevent or treat CAR-T enteritis, improving safety and quality of life for patients receiving BCMA CAR-T.
How similar studies have gone: Preliminary case reports suggest immune-related enteritis is a real issue, and deeper profiling could yield actionable targets.
Where this research is happening
-
University of California, San Francisco
San Francisco, United States Active
Researchers
- Principal investigator: Oh, David Yoonsuk — University of California, San Francisco
- Study coordinator: Oh, David Yoonsuk
Related research
Other NIH-funded projects on the same topics.
-
Integrative study of multiple myeloma genetics and disease biology
A team at Dana-Farber and partners is pursuing a long-term project to understand the genetic and molecular drivers of multiple myeloma and how treatments interact with disease biology.
-
Comparative Modeling to Prevent, Detect Early, and Treat Multiple Myeloma
A research team will build and compare computer models to understand how multiple myeloma develops, can be detected earlier, and treated more effectively.
-
How LDL Affects Multiple Myeloma: New Pathways to Keep Remission
A new grant is studying how cholesterol from LDL particles fuels multiple myeloma and how this interaction influences the tumor environment and immune response, with goals to help patients stay in remission.
-
Therapy-induced senescence and immune activation in multiple myeloma
A study in people with multiple myeloma will explore how treatment-related senescence in cancer cells may stimulate the immune system and affect cancer return after standard frontline therapy.
-
Understanding Drug-Resistant Multiple Myeloma to Stop Relapse
Researchers are studying why some myeloma cells resist treatment and how to create new therapies to prevent relapse.
-
Overcoming resistance to CART cell therapy in multiple myeloma
This grant aims to improve CAR T-cell therapy for people with multiple myeloma by tackling why some patients stop responding, using innovative approaches to boost cancer-fighting cells in the bone marrow.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.